

Dumb Drugs and Site of Care Matters Pilot Study



► Founded by Actuary and Pharmacist in 2014


- ▶ PBM consulting is more than vendor management
- Clinical programming emphasis
- ► Evolution of "PBM Enhancer", outcomes based
- Educate both brokers and clients
- ▶ No marketing or sales staff
- ➤ Strategic broker partnerships (75%), Direct (25%)
- ► Client Size Range 182 320,000 members
- > +70 clients, +700,000 members

Our Story...





Focus on Plan Value



Price is what you pay. Value is what you get.


Warren Buffett

*<u>Drug Utilization</u> Drives Plan Cost... Appropriate Drug Utilization Drives <u>Plan Value</u>





Appropriate Drug Utilization



Service Support and Patient Engagement



Pricing,

Performance,

and Auditing

Purposely Different, Purposefully Consultative

Clinical Risk Management

- Clinical resource for decision support
- Claims diagnostics decision support
- Appropriate formulary and clinical rules
- Non-Essential medication removal
- Specialty oversight and auditing
- Consultation on benefit design
- Plan performance review and strategy
- Validation PBM programs offered







Clinical Analytics

RxConnection Programs

Rx Defender

- Egregiously priced, new versions or combinations of med
- Targeted pharmacy challenges
- Pharmacy site of care

Specialty Defender

- Clinical management/protocols
- Coupon management, alternate funding
- Total specialty (Rx and Medical utilization and site of care)



What is RxDefender drug waste?

Synonyms:

Me Too, Non-Essential, Egregious, Gimmick, Scam, "Dumb Drugs"



Basics:

- Innovation has stalled on the non-specialty segment
- Rebate competition between PBMs provides opportunity for pharma
- Pressure to produce excessive profits on products with competition
- Pressure from pharmacies or physicians who have lost revenues due to compound edits or reimbursement reductions
- Medications identified in claims data as high cost then researched for clinical outcomes and comparable options to determine if significantly lower cost options could be easily substituted and clinically equivalent

Ivy Tech provided 1 year of data for pilot demonstration



RxDefender Analytics

What is Waste? >1,000 Meds, >6,500 NDCs

Patent Extenders	 Nexium, Dexilant, ER/XR
Brands with Generic	• Lipitor, Crestor, Wellbutrin
New Version	Glumetza, Pennsaid
New Combinations	• Duexis, Yosprala, Durlaza
Overpriced Generics	Metformin OSM, Omeprazole
Pharmacy Mitigation	Diclofenac, Lidocaine
Dermatology Oral	Absorica, Solodyne
Dermatology Topical	• Onexton, Alpawash
FDA Not Approved	• Donnatal, Librax

Prescribing pattern diagnostics: common pharmacy or prescriber **Challenge:** aggressive marketing, cold calling, pharmacy partners, and <u>coupons.</u>



ESI Group Plan Utilization

Category	Summary (Feb 2018-Jan 2019)
Member Count	41,278 (Avg)
Total Script Count	390,191
Total Gross Cost	\$66,098,679
Plan Cost	\$56,857,652
Member Cost	\$9,241,027
Generic Dispensing Rate	86.1%
Member Cost Share	14.0%
Mail Utilization %	23.3%
Total Specialty Spend	\$28,686,964
% of Total Spend- Specialty	43.4%
Avg Cost / Rx	\$169
Gross Cost PMPM	\$133
Plan Cost PMPM	\$115

Solid generic utilization, average specialty spend, but cost per rx and pmpm are both high and demonstrate opportunity.



RxDefender: Summary

RxDefender (Top 100)							
Clinical Analytics							
Claims Impacted	3,412	0.9%					
Members Impacted	1,452	3.5%					
Medications Impacted	100						
Gross Cost	\$3,697,759	5.6%					
Replacement Plan Cost	\$739,552						
Savings / Rx	\$867						
Savings / Member Impacted	\$2,037						
Total Gross Savings	\$2,958,207	4.5%					

This is Top 100 only the total RxDefender utilization opportunities found in:
185 Medications,
\$4.9M Gross Cost
7.3% of plan gross spend
(3-7% Norm).



RxDefender: Top 5

Mbrs	Claims	Gross Cost	Cost/Rx	Total Savings	Drug Name	Alternative	Alternate Cost/Rx	Savings/ Rx
3	8	\$318,325	\$39,791	\$250,325	H.P. ACTHAR	specialty TNF	\$8,500	\$31,291
32	119	\$232,830	\$1,957	\$185,230	ABSORICA	amnesteem	\$400	\$1,557
26	99	\$214,804	\$2,170	\$208,864	METFORMIN ER OSM	metformin ER	\$60	\$2,110
22	59	\$207,311	\$3,514	\$206,131	DUEXIS	ibuprofen + famotidine	\$20	\$3,494
21	49	\$175,605	\$3,584	\$174,135	CHLORZOXAZONE	chlorzoxazone (half tab)	\$30	\$3,554

\$1,024,686

*Metformin ER OSM and Chlorzoxazone are generic medications.



RxDefender: High Cost Generics

	Top 5 Generic Opportunities										
Mbrs	Claims	Gross Cost	Cost/Rx	Total Savings	Drug Name	Alternative	Alternate Cost/Rx	Savings/ Rx			
26	99	\$214,804	\$2,170	\$208,864	METFORMIN ER OSM	metformin ER	\$60	\$2,110			
21	49	\$175,605	\$3,584	\$174,135	CHLORZOXAZONE	chlorzoxazone (half tab)	\$30	\$3,554			
6	30	\$110,020	\$3,667	\$105,520	DIHYDROERGOTAMINE MES	sumatriptan nasal	\$150	\$3,517			
44	122	\$78,602	\$644	\$72,502	VENLAFAXINE HCL ER	venlafaxine er caps	\$50	\$594			
49	182	\$68,605	\$377	\$64,965	ELETRIPTAN	sumatriptan	\$20	\$357			

\$625,986



RxDefender: Brand with Generic

\$255,562

	Top 5 BRANDS WITH A GENERIC Opportunities										
Mbrs	Claims	Gross Cost	Cost/Rx	Total Savings	Drug Name	Alternative	Alternate Cost/Rx	Savings/ Rx			
6	36	\$100,284	\$2,786	\$98,124	WELLBUTRIN XL	bupropion XL	\$60	\$2,726			
3	8	\$91,549	\$11,444	\$75,549	TOBI PODHALER	tobramycin inhalation	\$2,000	\$9,444			
19	28	\$54,334	\$1,940	\$37,534	UCERIS	budesonide ER	\$600	\$1,340			
13	48	\$26,574	\$554	\$25,134	NEXIUM	esomeprazole	\$30	\$524			
15	43	\$21,801	\$507	\$19,221	ALPHAGAN P	brimonidine	\$60	\$447			



RxDefender Pilot



- Largest singly-accredited community college in the country
- 3,200 Full-Time Employees, 87% enrolled in health plan
 - 5,700 members
- CVS Caremark since 2018
 - Members of IAPPP
- Coverage is unique to the specific medical plan (offer two different plans)





RxDefender: Summary



RxDefender							
Clinical Analytics							
Claims Impacted	1,235 (1.5%)						
Medications Impacted	83						
Gross Cost	\$694,152						
Est. Replacement Plan Cost	\$138,830						
Savings / Rx	\$450						
% of Total Gross Cost	6.5%						
Total Gross Savings	\$555,322						

(3-7% Norm).



RxDefender: Top 10

	Top 10 NON-ESSENTIAL Opportunities										
Mbrs	Claim Count	Gross Cost	Cost/ Rx	Total Savings	Drug Name	Alternative	Alt Cost/Rx	Savings/ Rx			
2	24	\$58,788	\$2,449	\$57,348	WELLBUTRIN	generic	\$60	\$2,389			
3	22	\$53,407	\$2,428	\$53,187	DUEXIS	ibuprofen / pepcid	\$10	\$2,418			
12	73	\$45,466	\$623	\$42,546	TROKENDI	topiramate IR	\$40	\$583			
6	31	\$41,610	\$1,342	\$39,750	METFORMIN ER OSM	metformin ER	\$60	\$1,282			
16	96	\$32,936	\$343	\$31,496	DEXILANT	omeprazole	\$15	\$328			
20	120	\$32,396	\$270	\$30,596	ESOMEPRAZOLE (Nexium)	omeprazole	\$15	\$255			
4	36	\$27,634	\$768	\$25,474	GRALISE	gabapentin	\$60	\$708			
6	40	\$25,224	\$631	\$23,224	DOXYCYCLINE	doxycycline	\$50	\$581			
7	34	\$18,828	\$554	\$18,488	XIIDRA	artificial tears	\$10	\$544			
3	28	\$18,310	\$654	\$7,670	VENLAFAXINE TAB	venlafaxine cap	\$40	\$614			

\$339,298



RxDefender: Breakdown

	Top 10 NON-ESSSENTIAL Opportunities									
Mbrs	Cnt	Gross Cost	Cost/ Rx	Total Savings	Drug Name	Alternative	Alt Cost/Rx	Savings /Rx		
2	24	\$58,788	\$2,449	\$57,348	WELLBUTRIN	generic	\$60	\$2,389		
3	22	\$53,407	\$2,428	\$53,187	DUEXIS	ibuprofen / pepcid	\$10	\$2,418		
12	73	\$45,466	\$623	\$42,546	TROKENDI	topiramate IR	\$40	\$583		
6	31	\$41,610	\$1,342	\$39,750	METFORMIN ER OSM	metformin ER	\$60	\$1,282		
16	96	\$32,936	\$343	\$31,496	DEXILANT	omeprazole	\$15	\$328		
20	120	\$32,396	\$270	\$30,596	ESOMEPRAZOLE	omeprazole	\$15	\$255		
4	36	\$27,634	\$768	\$25,474	GRALISE	gabapentin	\$60	\$708		
6	40	\$25,224	\$631	\$23,224	DOXYCYCLINE	doxycycline	\$50	\$581		
7	34	\$18,828	\$554	\$18,488	XIIDRA	artificial tears	\$10	\$544		
3	28	\$18,310	\$654	\$7,670	VENLAFAXINE TAB	venlafaxine cap	\$40	\$614		

Major/no rebate impact

Rebate challenges

Generic, No rebate

\$339,298



RxDefender: Targeted Pharmacy

Top 5 RxDefender Targeted Pharmacies							
Pharmacy	Claims	Gross Cost	Cost/Rx	Concern			
PEOPLE'S DRUG STORE	25	\$60,690	\$2,428	Duexis, Vimovo			
CAREPOINT INDIANA LLC	65	\$39,754	\$750	Dermatology			
LONG PRAIRIE PHARMACY	36	\$21,072	\$1,003	Dermatology			
INNOVATIVE RX	8	\$10,981	\$1,372	Creams/Muscle Rel			
FLORIDA MEDICINE STORE	3	\$5,690	\$1,897	Pain Creams			

\$147,391

Reviewed file for independent pharmacies which are filling RxDefender medications ONLY. Those in Yellow highest concern.



RxDefender: Site of Care

Top 5 SITE OF CARE Opportunities

Mbrs	Claim Cnt	Gross Cost	Cost/ Rx	Total Savings	Drug Name	Alternative	Alt Cost/Rx	Savings/ Rx
1	1	\$5,440	\$5,440	\$4,660	IMATINIB 400MG (GLEEVEC)	Specialty move to Retail	\$780	\$4,660
1	6	\$15,700	\$2,616	\$10,896	CAPECITABINE 500MG (XELODA)	Specialty move to Retail	\$800	\$1,816
1	4	\$2,891	\$722	\$1,288	DOFETILIDE 500MG (TIKOSYN)	Specialty move to Retail	\$400	\$322
1	5	\$3,640	\$728	\$2,415	ABA/LAMIV 600/300 (EPZICOM)	Specialty move to Retail	\$245	\$483
1	12	\$7,376	\$614	\$6,888	SILDENAFIL 20MG (REVATIO)	Specialty move to Retail	\$40	\$574

\$26,147

PBM Contract may not allow you to move the site of distribution.

Goal is potentially move or match price.



RxDefender Pilot



- Initial thoughts
- Where do we go from here?



Insanity: doing the same thing over and over again and expecting different results.

Unknown

The Challenge:

Evolving from spreadsheet managers to risk/cost managers.

Final Thoughts with Q&A



